Conditions: Hepatitis C
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 50
Healthy volunteers: yes

Brief summary:
This study will compare the pharmacokinetics (PK) of grazoprevir (MK-5172) when administered to participants with mild, moderate or severe hepatic insufficiency (assessed by the criteria of the Child-Pugh's scale) with the PK of grazoprevir when administered to healthy participants.

Detailed description:

Arms:
arm 1: Participants with mild hepatic impairment will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study. arm 2: Healthy participants will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study. arm 3: Participants with moderate hepatic impairment will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study. arm 4: Healthy participants will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study. arm 5: Participants with severe hepatic impairment will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study. arm 6: Healthy participants will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.

Interventions: intervention 1: Grazoprevir
Intervention descriptions: intervention 1: Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days

Protocol document: